Fay Kastrinos1, Myles A Ingram2, Elisabeth R Silver2, Aaron Oh2, Monika Laszkowska3, Anil K Rustgi3, Chin Hur4. 1. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York; Division of Digestive and Liver Diseases, Columbia University Irving Medical Cancer and Vagelos College of Physicians and Surgeons, New York, New York. Electronic address: Fk18@columbia.edu. 2. Division of General Medicine, Columbia University Irving Medical Cancer and Vagelos College of Physicians and Surgeons, New York, New York. 3. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York; Division of Digestive and Liver Diseases, Columbia University Irving Medical Cancer and Vagelos College of Physicians and Surgeons, New York, New York. 4. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York; Division of Digestive and Liver Diseases, Columbia University Irving Medical Cancer and Vagelos College of Physicians and Surgeons, New York, New York; Division of General Medicine, Columbia University Irving Medical Cancer and Vagelos College of Physicians and Surgeons, New York, New York.
Abstract
BACKGROUND AND AIMS: Lynch syndrome is associated with pathogenic variants in 4 mismatch repair (MMR) genes that increase lifetime risk of colorectal cancer. Guidelines recommend intensive colorectal cancer surveillance with colonoscopy every 1-2 years starting at age 25 years for all carriers of Lynch syndrome-associated variants, regardless of gene product. We constructed a simulation model to analyze the effects of different ages of colonoscopy initiation and surveillance intervals for each MMR gene (MLH1, MSH2, MSH6, and PMS2) on colorectal cancer incidence and mortality, quality-adjusted life-years, and cost. METHODS: Using published literature, we developed a Markov simulation model of Lynch syndrome progression for patients with each MMR variant. The model simulated clinical trials of Lynch syndrome carriers, varying age of colonoscopy initiation (5-year increments from 25-40 years), and surveillance intervals (1-5 years). We assessed the optimal strategy for each gene, defined as the strategy with the highest quality-adjusted life-years and incremental cost-effectiveness ratio below a $100,000 willingness-to-pay threshold. RESULTS: Optimal surveillance for patients with pathogenic variants in the MLH1 and MSH2 genes was colonoscopy starting at age 25 years, with 1- to 2-year surveillance intervals. Initiating colonoscopy at age 35 and 40 years, with 3-year intervals, was cost-effective for patients with pathogenic variants in MSH6 or PMS2, respectively. CONCLUSIONS: We developed a simulation model to select optimal surveillance starting ages and intervals for patients with Lynch syndrome based on MMR variant. The model supports recommendations for intensive surveillance of patients with Lynch syndrome-associated variants in MLH1 or MSH2. However, for patients with Lynch syndrome-associated variants of MSH6 or PMS2, later initiation of surveillance at 35 and 40 years, respectively, and at 3-year intervals, can be considered.
BACKGROUND AND AIMS: Lynch syndrome is associated with pathogenic variants in 4 mismatch repair (MMR) genes that increase lifetime risk of colorectal cancer. Guidelines recommend intensive colorectal cancer surveillance with colonoscopy every 1-2 years starting at age 25 years for all carriers of Lynch syndrome-associated variants, regardless of gene product. We constructed a simulation model to analyze the effects of different ages of colonoscopy initiation and surveillance intervals for each MMR gene (MLH1, MSH2, MSH6, and PMS2) on colorectal cancer incidence and mortality, quality-adjusted life-years, and cost. METHODS: Using published literature, we developed a Markov simulation model of Lynch syndrome progression for patients with each MMR variant. The model simulated clinical trials of Lynch syndrome carriers, varying age of colonoscopy initiation (5-year increments from 25-40 years), and surveillance intervals (1-5 years). We assessed the optimal strategy for each gene, defined as the strategy with the highest quality-adjusted life-years and incremental cost-effectiveness ratio below a $100,000 willingness-to-pay threshold. RESULTS: Optimal surveillance for patients with pathogenic variants in the MLH1 and MSH2 genes was colonoscopy starting at age 25 years, with 1- to 2-year surveillance intervals. Initiating colonoscopy at age 35 and 40 years, with 3-year intervals, was cost-effective for patients with pathogenic variants in MSH6 or PMS2, respectively. CONCLUSIONS: We developed a simulation model to select optimal surveillance starting ages and intervals for patients with Lynch syndrome based on MMR variant. The model supports recommendations for intensive surveillance of patients with Lynch syndrome-associated variants in MLH1 or MSH2. However, for patients with Lynch syndrome-associated variants of MSH6 or PMS2, later initiation of surveillance at 35 and 40 years, respectively, and at 3-year intervals, can be considered.
Authors: Christoph Engel; Aysel Ahadova; Toni T Seppälä; Stefan Aretz; Marloes Bigirwamungu-Bargeman; Hendrik Bläker; Karolin Bucksch; Reinhard Büttner; Wouter T de Vos Tot Nederveen Cappel; Volker Endris; Elke Holinski-Feder; Stefanie Holzapfel; Robert Hüneburg; Maarten A J M Jacobs; Jan J Koornstra; Alexandra M Langers; Anna Lepistö; Monika Morak; Gabriela Möslein; Päivi Peltomäki; Kirsi Pylvänäinen; Nils Rahner; Laura Renkonen-Sinisalo; Karsten Schulmann; Verena Steinke-Lange; Albrecht Stenzinger; Christian P Strassburg; Paul C van de Meeberg; Mariette van Kouwen; Monique van Leerdam; Deepak B Vangala; Juda Vecht; Marie-Louise Verhulst; Magnus von Knebel Doeberitz; Jürgen Weitz; Silke Zachariae; Markus Loeffler; Jukka-Pekka Mecklin; Matthias Kloor; Hans F Vasen Journal: Gastroenterology Date: 2020-01-08 Impact factor: 22.682
Authors: Anne Goverde; Ellis L Eikenboom; Ellemieke L Viskil; Marco J Bruno; Michael Doukas; Winand N M Dinjens; Erik Jan Dubbink; Ans M W van den Ouweland; Robert M W Hofstra; Anja Wagner; Manon C W Spaander Journal: Clin Gastroenterol Hepatol Date: 2019-08-27 Impact factor: 11.382
Authors: Elena Stoffel; Bhramar Mukherjee; Victoria M Raymond; Nabihah Tayob; Fay Kastrinos; Jennifer Sparr; Fei Wang; Prathap Bandipalliam; Sapna Syngal; Stephen B Gruber Journal: Gastroenterology Date: 2009-07-18 Impact factor: 22.682
Authors: Sanne W Ten Broeke; Heleen M van der Klift; Carli M J Tops; Stefan Aretz; Inge Bernstein; Daniel D Buchanan; Albert de la Chapelle; Gabriel Capella; Mark Clendenning; Christoph Engel; Steven Gallinger; Encarna Gomez Garcia; Jane C Figueiredo; Robert Haile; Heather L Hampel; John L Hopper; Nicoline Hoogerbrugge; Magnus von Knebel Doeberitz; Loic Le Marchand; Tom G W Letteboer; Mark A Jenkins; Annika Lindblom; Noralane M Lindor; Arjen R Mensenkamp; Pål Møller; Polly A Newcomb; Theo A M van Os; Rachel Pearlman; Marta Pineda; Nils Rahner; Egbert J W Redeker; Maran J W Olderode-Berends; Christophe Rosty; Hans K Schackert; Rodney Scott; Leigha Senter; Liesbeth Spruijt; Verena Steinke-Lange; Manon Suerink; Stephen Thibodeau; Yvonne J Vos; Anja Wagner; Ingrid Winship; Frederik J Hes; Hans F A Vasen; Juul T Wijnen; Maartje Nielsen; Aung Ko Win Journal: J Clin Oncol Date: 2018-08-30 Impact factor: 50.717
Authors: Mev Dominguez-Valentin; Julian R Sampson; Toni T Seppälä; Sanne W Ten Broeke; John-Paul Plazzer; Sigve Nakken; Christoph Engel; Stefan Aretz; Mark A Jenkins; Lone Sunde; Inge Bernstein; Gabriel Capella; Francesc Balaguer; Huw Thomas; D Gareth Evans; John Burn; Marc Greenblatt; Eivind Hovig; Wouter H de Vos Tot Nederveen Cappel; Rolf H Sijmons; Lucio Bertario; Maria Grazia Tibiletti; Giulia Martina Cavestro; Annika Lindblom; Adriana Della Valle; Francisco Lopez-Köstner; Nathan Gluck; Lior H Katz; Karl Heinimann; Carlos A Vaccaro; Reinhard Büttner; Heike Görgens; Elke Holinski-Feder; Monika Morak; Stefanie Holzapfel; Robert Hüneburg; Magnus von Knebel Doeberitz; Markus Loeffler; Nils Rahner; Hans K Schackert; Verena Steinke-Lange; Wolff Schmiegel; Deepak Vangala; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; John L Hopper; Aung Ko Win; Robert W Haile; Noralane M Lindor; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Jane C Figueiredo; Stephen N Thibodeau; Karin Wadt; Christina Therkildsen; Henrik Okkels; Zohreh Ketabi; Leticia Moreira; Ariadna Sánchez; Miquel Serra-Burriel; Marta Pineda; Matilde Navarro; Ignacio Blanco; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Oliver G Denton; Ian M Frayling; Einar Andreas Rødland; Hans Vasen; Miriam Mints; Florencia Neffa; Patricia Esperon; Karin Alvarez; Revital Kariv; Guy Rosner; Tamara Alejandra Pinero; María Laura Gonzalez; Pablo Kalfayan; Douglas Tjandra; Ingrid M Winship; Finlay Macrae; Gabriela Möslein; Jukka-Pekka Mecklin; Maartje Nielsen; Pål Møller Journal: Genet Med Date: 2019-07-24 Impact factor: 8.822
Authors: Toni T Seppälä; Aysel Ahadova; Mev Dominguez-Valentin; Finlay Macrae; D Gareth Evans; Christina Therkildsen; Julian Sampson; Rodney Scott; John Burn; Gabriela Möslein; Inge Bernstein; Elke Holinski-Feder; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; Anna Lepistö; Charlotte Kvist Lautrup; Annika Lindblom; John-Paul Plazzer; Ingrid Winship; Douglas Tjandra; Lior H Katz; Stefan Aretz; Robert Hüneburg; Stefanie Holzapfel; Karl Heinimann; Adriana Della Valle; Florencia Neffa; Nathan Gluck; Wouter H de Vos Tot Nederveen Cappel; Hans Vasen; Monika Morak; Verena Steinke-Lange; Christoph Engel; Nils Rahner; Wolff Schmiegel; Deepak Vangala; Huw Thomas; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Gabriel Capella; Marta Pineda; Matilde Navarro; Ignacio Blanco; Sanne Ten Broeke; Maartje Nielsen; Ken Ljungmann; Sigve Nakken; Noralane Lindor; Ian Frayling; Eivind Hovig; Lone Sunde; Matthias Kloor; Jukka-Pekka Mecklin; Mette Kalager; Pål Møller Journal: Hered Cancer Clin Pract Date: 2019-02-28 Impact factor: 2.857
Authors: Elsa L S A van Liere; Nanne K H de Boer; Evelien Dekker; Monique E van Leerdam; Tim G J de Meij; Dewkoemar Ramsoekh Journal: Aliment Pharmacol Ther Date: 2022-02-18 Impact factor: 9.524